Guardant Health Financial Statements (GH)
|
|
|
|
Report date
|
|
|
24.02.2022 |
23.02.2023 |
22.02.2024 |
20.02.2025 |
19.02.2026 |
|
19.02.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
373.7 |
449.5 |
563.9 |
739.0 |
982.0 |
|
982.0 |
|
Operating Income, bln rub |
|
|
-411.0 |
-544.4 |
-564.7 |
-443.6 |
-436.3 |
|
-437.2 |
|
EBITDA, bln rub |
? |
|
-359.6 |
-614.9 |
-433.3 |
-390.1 |
-373.9 |
|
-373.9 |
|
Net profit, bln rub |
? |
|
-405.7 |
-654.6 |
-479.4 |
-436.4 |
-416.3 |
|
-416.3 |
|
|
OCF, bln rub |
? |
|
-209.0 |
-309.5 |
-325.0 |
-239.9 |
-184.8 |
|
-172.5 |
|
CAPEX, bln rub |
? |
|
75.0 |
77.5 |
20.5 |
35.1 |
48.3 |
|
48.3 |
|
FCF, bln rub |
? |
|
-284.1 |
-386.9 |
-345.5 |
-274.9 |
-233.1 |
|
-220.8 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
661.7 |
837.6 |
901.6 |
892.8 |
1 070 |
|
1 070 |
|
Cost of production, bln rub |
|
|
122.9 |
156.3 |
227.1 |
289.8 |
349.0 |
|
349.0 |
|
R&D, bln rub |
|
|
263.2 |
373.8 |
367.2 |
347.8 |
364.2 |
|
364.2 |
|
Interest expenses, bln rub |
|
|
2.58 |
2.58 |
2.58 |
2.58 |
3.90 |
|
3.90 |
|
|
Assets, bln rub |
|
|
2 204 |
1 610 |
1 786 |
1 486 |
2 014 |
|
2 014 |
|
Net Assets, bln rub |
? |
|
645.0 |
60.2 |
158.7 |
-139.6 |
-99.3 |
|
-99.3 |
|
Debt, bln rub |
|
|
1 374 |
1 369 |
1 354 |
1 336 |
1 682 |
|
1 682 |
|
Cash, bln rub |
|
|
932.7 |
1 011 |
1 169 |
840.0 |
1 202 |
|
1 202 |
|
Net debt, bln rub |
|
|
441.0 |
358.1 |
185.1 |
496.1 |
480.9 |
|
480.9 |
|
|
Ordinary share price, rub |
|
|
100.0 |
27.2 |
27.1 |
30.6 |
102.1 |
|
26.9 |
|
Number of ordinary shares, mln |
|
|
101.3 |
102.2 |
112.0 |
122.7 |
125.4 |
|
128.7 |
|
|
Market cap, bln rub |
|
|
10 133 |
2 779 |
3 029 |
3 750 |
12 806 |
|
3 458 |
|
EV, bln rub |
? |
|
10 574 |
3 137 |
3 214 |
4 246 |
13 287 |
|
3 939 |
|
Book value, bln rub |
|
|
628 |
45 |
146 |
-150 |
-202 |
|
-202 |
|
|
EPS, rub |
? |
|
-4.00 |
-6.41 |
-4.28 |
-3.56 |
-3.32 |
|
-3.24 |
|
FCF/share, rub |
|
|
-2.80 |
-3.79 |
-3.08 |
-2.24 |
-1.86 |
|
-1.72 |
|
BV/share, rub |
|
|
6.19 |
0.44 |
1.31 |
-1.22 |
-1.62 |
|
-1.57 |
|
|
EBITDA margin, % |
? |
|
-96.2% |
-136.8% |
-76.8% |
-52.8% |
-38.1% |
|
-38.1% |
|
Net margin, % |
? |
|
-108.6% |
-145.6% |
-85.0% |
-59.0% |
-42.4% |
|
-42.4% |
|
FCF yield, % |
? |
|
-2.80% |
-13.9% |
-11.4% |
-7.33% |
-1.82% |
|
-6.38% |
|
ROE, % |
? |
|
-62.9% |
-1 088% |
-302.1% |
312.5% |
419.2% |
|
419.2% |
|
ROA, % |
? |
|
-18.4% |
-40.7% |
-26.8% |
-29.4% |
-20.7% |
|
-20.7% |
|
|
P/E |
? |
|
-25.0 |
-4.25 |
-6.32 |
-8.59 |
-30.8 |
|
-8.31 |
|
P/FCF |
|
|
-35.7 |
-7.18 |
-8.77 |
-13.6 |
-54.9 |
|
-15.7 |
|
P/S |
? |
|
27.1 |
6.18 |
5.37 |
5.07 |
13.0 |
|
3.52 |
|
P/BV |
? |
|
16.1 |
61.5 |
20.7 |
-25.0 |
-63.2 |
|
-17.1 |
|
EV/EBITDA |
? |
|
-29.4 |
-5.10 |
-7.42 |
-10.9 |
-35.5 |
|
-10.5 |
|
Debt/EBITDA |
|
|
-1.23 |
-0.58 |
-0.43 |
-1.27 |
-1.29 |
|
-1.29 |
|
|
R&D/CAPEX, % |
|
|
350.8% |
482.6% |
1 792% |
991.2% |
753.9% |
|
753.9% |
|
|
CAPEX/Revenue, % |
|
|
20.1% |
17.2% |
3.63% |
4.75% |
4.92% |
|
4.92% |
|
| Guardant Health shareholders |
